New HIV Prevention Injection Offered in South Africa

A groundbreaking new HIV prevention injection is now being offered to a limited number of individuals in South Africa, providing two months of protection with a single shot. Administered outside of clinical trials, the injection contains a long-acting formulation of the antiretroviral drug cabotegravir (CAB-LA), offering a more convenient and less painful alternative to traditional methods of prevention. Select individuals in South Africa have access to it through pilot projects such as the FAST PrEP study, aiming to introduce the injectable and gather valuable insights for future large-scale implementation.